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Abstract
The mortality for acute respiratory distress syndrome (ARDS) remains unacceptably
high. Success in clinical trials has been limited, resulting in a lack of effective therapies to treat
the syndrome. The projected increase in mechanically ventilated patients and global need for
critical care services suggests that the clinical and research landscape in ARDS can no longer be
confined to the intensive care unit (ICU). A demonstrable minority of patients present to the
emergency department (ED) with ARDS, and ARDS onset typically occurs shortly after ICU
admission. Furthermore, the ED is an entry point for many of the highest risk patients for ARDS
development and progression. These facts, combined with prolonged lengths of stay in the ED,
suggest that the ED could represent a window of opportunity for treatment and preventive
strategies, as well as clinical trial enrollment. This review aims to discuss some of the potential
strategies which may prevent or alter the trajectory of ARDS, with a focus on the potential role
the ED could play in reducing the burden of this syndrome.

Keywords
acute respiratory distress syndrome, emergency department, prevention
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Introduction
The landscape of critical care provided in the emergency department
Decades ago, delivery of critical care was envisioned to extend from the prehospital
environment and into the intensive care unit (ICU). The emergency department (ED) was
recognized as an important link in the care of the critically ill (1). Today, with over 100 million
visits annually and increasing lengths of stay before inpatient admission, critical care is being
provided in the ED more than ever (2, 3). With higher acuity in patient presentation, scarcity of
available critical care beds, and impact of ED lengths of stay on critical care outcomes, the ED
has become an increasingly important treatment location for the critically ill (3-9). Overcrowding
is a recognized threat to patient safety, and delays in admission of critically ill patients to the
ICU suggest that targeted interventions should be provided as soon as possible, regardless of
patient location (4). Although time spent in the ED is a small fraction of the total inpatient stay,
several series have demonstrated the early period of critical illness as being a particularly
vulnerable time, where appropriate interventions have potential to change morbidity and
mortality (10-12). Given these realities, the ED has proven to be an ideal setting to conduct
research of early critical illness (11, 13).
This research agenda has yet to extend to mechanical ventilation and acute respiratory
distress syndrome (ARDS) to any great degree however (14). Observational data suggest that the
onset of ARDS is within hours to days after ICU admission (15-19). Endotracheal intubation and
initiation of mechanical ventilation is common in the ED (20). Despite this, there is a lack of
evidence regarding mechanical ventilation practices in the ED or the effect of ED care and
mechanical ventilation on ARDS progression and outcome (12, 21). Therapeutic momentum
initiated in the ED is often continued after admission (11, 12, 22). Given the influence of early
interventions on outcome with other time-sensitive emergencies (e.g. sepsis and trauma), there is
potential that this paradigm can be extended to ARDS prevention and treatment as well. The aim
4

of this review is to discuss some of the early interventions that can potentially prevent or alter the
trajectory of ARDS, with some focus on the potential role the ED may play in the care of
patients with or at risk for ARDS.

The current landscape of ARDS
ED prevalence and rate of progression after admission
ARDS affects close to 200,000 patients annually in the United States, and despite an
overall improvement in mortality, remains a highly lethal condition (23, 24). Survivors of ARDS
exhibit long-term morbidity across a wide range of important clinical outcomes, therefore its
impact on public health is significant (23, 24). Despite extensive research, only low tidal volume
ventilation has shown consistent survival benefit across syndrome severity, with prone
positioning beneficial in the sickest ARDS cohort when instituted early and for prolonged
periods (25-27). Prior clinical trials have focused extensively on patients in the ICU, less so in
the operating room (OR), and little to none in the ED (14). Limited observational data focusing
exclusively on ED patients suggests that a significant minority of patients have ARDS while in
the ED, with a prevalence rate of 8.8% in mechanically ventilated patients with severe sepsis and
septic shock (a high-risk cohort for the syndrome) (12). Larger observational studies of early
ARDS have estimated an ED ARDS prevalence between 7 and 8.7% (21, 28).
Progression to ARDS represents a seminal event for the critically ill patient, that not only
worsens pulmonary function (Figure 1), but also increases morbidity and mortality (14). At the
intersection between patient risk and treatment variables, ARDS can be insidious and cryptic in
onset, and often goes unrecognized by treating clinicians; this under-recognition of ARDS may
contribute to the suboptimal translation of outcome-improving evidence to the bedside (Figure
2) (29-32). Risk factors for progression to ARDS have been described for decades, yet predicting
ARDS at an individual patient level can be difficult. ARDS, despite a consensus definition of the
5

syndrome, is likely not a “yes/no” diagnosis, but rather a spectrum of inflammatory pulmonary
failure. Patients progressing to ARDS have higher levels of inflammatory markers, both in
bronchoalveolar lavage and serum (33). Imaging studies have shown high levels of neutrophilic
inflammation in patients at risk for ARDS, but in whom the definitional criteria have not been
met (NCT01486342). These data suggest that patients at high risk for ARDS have “pre-injured”
lungs, and the progression to ARDS is a potentially modifiable continuum (Figure 3). A
prospective, multicenter observational cohort study assessing patient conditions and risk
modifiers, created a lung injury prediction score (LIPS), identifying patients at high risk (34).
ED-based studies suggest an ARDS progression rate after admission of 27.5% in patients with
severe sepsis and septic shock (12). Cohort studies from the ICU and one randomized controlled
trial have cited an ARDS progression rate of 6.2% to 44% with a median onset of approximately
2 days (14, 33, 35). The prevalence of ARDS after ED admission, as well as the early onset,
further suggests that therapeutic interventions in critically ill patients should not be constrained
by the geographic location of the patient in a hospital. The time spent and treatment provided in
the ED, and early ICU, could potentially alter the course of ARDS.

Therapy to alter the trajectory of ARDS
Mechanical ventilation strategies
Tidal volume
Normal mammalian tidal volume, indexed to size, is less than 7mL/kg, and was the tidal
volume target used in a landmark ARDS clinical trial (25, 36). The success of that trial
comparing relatively normal tidal volume to a “conventional” tidal volume showed that
essentially normal tidal volume improved outcome. Despite the short- and long-term outcome
benefit of low tidal volume ventilation in ARDS, adherence to this strategy in ICU patients
remains poor (32). In patients without ARDS, there is no consensus on the most appropriate tidal
6

volume to use, and this represents an area of debate (37-40). In patients at very low risk for
ARDS, especially with an exposure time to mechanical ventilation that is limited (e.g. healthy
elective surgical patients), the chosen tidal volume strategy may not be clinically important (41).
However, an increase in serum and bronchoalveolar lavage biomarkers suggests that deleterious
mechanical ventilation can induce lung damage even with very time-limited ventilation (42-46).
Recent data also showed that lung-protective ventilation in the OR was associated with a
decrease in the composite outcome of major pulmonary complications and a trend in reduction of
ARDS in elective abdominal surgical patients (47).
In contrast to most OR patients, mechanically ventilated ED patients will be admitted to
the ICU and have a much longer exposure to mechanical ventilation (12). In these pre-injured
lungs, conventional tidal volume may serve as another “hit”, promoting the development of
ARDS after ICU admission (33). Many mechanically ventilated ED patients are exposed to high
tidal volume and lung-protective ventilation is uncommon in these patients (12, 21).
Clinical data suggests a causal link to tidal volume and ARDS progression in critically ill
patients (15, 16, 18, 33, 48-50). In the only randomized ICU trial on this topic to date, ventilation
with 6mL/kg predicted body weight (PBW) vs. 10mL/kg PBW showed a 10.9% absolute risk
reduction for ARDS progression, although the trial was stopped early for safety (33, 51). A
recent systematic review and meta-analysis showed a decrease in ARDS development with the
use of lower tidal volume (52). Another systematic review which included only studies
examining tidal volume in isolation, also showed that the majority of data suggests that higher
tidal volume is associated with ARDS progression (14). These findings are physiologically
consistent with randomized controlled trials (RCT) demonstrating that ventilation with lower
tidal volume reduces mortality in existing ARDS (25, 53, 54). These reviews also showed that
the use of low tidal volume in the OR and ICU is not harmful in patients without ARDS (14, 52).
A similar safety profile should be seen in the ED, given that respiratory rate is adjusted to meet
7

metabolic and ventilatory demands, and positive end-expiratory pressure is used to prevent
atelectasis (55).
Given the risk of progression to ARDS after emergency admission, the early progression
to ARDS after admission from the ED, and a lack of ED mechanical ventilation trials, low tidal
volume ventilation initiated in the ED should be studied further.

Positive end-expiratory pressure (PEEP)
Repetitive opening and closing of alveolar units at low lung volumes can contribute to
injury (i.e. atelectrauma). In patients with hypoxia due to atelectasis, alveolar edema and/or
volume loss, PEEP serves to restore functional residual capacity (FRC) and prevent endexpiratory volume loss (derecruitment) (56). Animal and ex-vivo lung model data has shown that
PEEP can protect the lung when compared to no, or very little, PEEP (57, 58). Beyond that, the
optimal level to set PEEP is less clear. In patients with established ARDS already receiving low
tidal volume ventilation, higher PEEP levels were not associated with improved clinical
outcomes, though a systematic review and meta-analysis suggested that patients with more
severe ARDS may benefit from higher PEEP(59-62).
The majority of patients in the ED in our center are treated with a PEEP of 5 cm H 2O
(12). In OR patients, higher PEEP levels are associated with a decrease in inflammatory
mediators, suggesting that a potential biological signal for protection exists (44, 63). Higher
levels of PEEP will improve oxygenation and lung compliance, but the use of higher PEEP in all
patients to prevent lung injury cannot be recommended at this time, as it is possible that higher
PEEP may overdistend ventral lung units and promote lung injury (60-62, 64). However, obesity
is a known risk factor for ARDS development, as these patients have elevated pleural pressure
and are therefore prone to end-expiratory alveolar collapse (12, 65). These patients may be better
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suited to higher PEEP levels for ARDS prevention, as well as frequent re-positioning, and the
use of prophylactic prone or semi-prone position (55, 66).

Airway pressure release ventilation (APRV)
The manner in which the lung is strained influences the development of lung injury.
Repetitive, breath-by-breath tidal ventilation appears to be more damaging than static strain and
deformation (67-69). Whereas conventional modes of mechanical ventilation elevate airway
pressure up from a set baseline to accomplish tidal ventilation, APRV employs sustained
pressure over time to maintain recruitment and mean airway pressure. In an animal model, the
early application of APRV before clinical lung injury, resulted in less pulmonary inflammation
and edema, with preserved gross and histological lung architecture (70, 71). The clinical
application of this mode of ventilation in a single center has been associated with low incidence
of ARDS in a trauma population as well but no controlled human studies have uniformly
supported this practice (72). There is a theoretical concern for uncontrolled, large tidal volumes
with APRV, as manifested by large volumes during the release phase. How these large volumes
potentially contribute to lung injury, given the more static nature of APRV, is not fully known.

Non-invasive ventilation
The use of non-invasive ventilation is common in ED patients with dyspnea, and has
been shown to reduce mortality in patients with reversible causes of respiratory failure, such as
cardiogenic pulmonary edema and chronic obstructive pulmonary disease (73, 74). Data
supporting its use in prevention of ARDS is less robust. Several small studies have shown a
decrease in intubation rates with early application of non-invasive ventilation in
immunocompromised patients (75, 76). However, given the limited data, and with a failure rate
of close to 50% in lung injury patients, the use of non-invasive ventilation should be assessed on
9

an individual patient-level basis, with frequent reassessment of pulmonary mechanics in effort to
avoid delay of appropriate and timely endotracheal intubation (77). Delayed intubation, in favor
of a trial of non-invasive ventilation, has been associated with an increase incidence in adverse
events, such as cardiac arrest, nosocomial pneumonia, and stress ulcers (78).

Non-ventilatory strategies
Fluid management
The Berlin definition of ARDS removed the requirement for a pulmonary artery
occlusion pressure ≤18mmHg to distinguish between ARDS and volume overload (79). This
change was more of a reflection of the limitations of that hemodynamic parameter and the
declining use of pulmonary artery catheters, rather than demoting the importance of fluid in
ARDS pathophysiology. Elevated left atrial pressure and ARDS frequently coexist, suggesting
that any increase in edema-promoting forces can increase edema and worsen pulmonary function
(80). Edema in injured lungs is both oncotic (e.g. capillary leak) and hydrostatic in nature. This
suggests (based on Starling forces) that actively lowering hydrostatic pressures (or at minimum
preventing unnecessary volume administration) should be beneficial. The association between
volume excess and clinical outcomes across multiple patients cohorts (e.g. sepsis, mechanical
ventilation, elective surgery, and acute kidney injury) is being increasingly recognized (81-88).
With respect to ARDS, many clinical scenarios that predispose to the syndrome can be
associated with extensive fluid requirements during resuscitation (e.g. septic shock and trauma).
While it seems paradoxical that aggressive fluid resuscitation could decrease ARDS, this
highlights the importance of timing in fluid administration. In patients with severe sepsis and
septic shock, early “aggressive” fluid administration was associated with a decrease in the need
for mechanical ventilation, as well as decreased inflammatory biomarkers, suggesting that early
reversal of global tissue hypoxia promotes pulmonary integrity at an endothelial and epithelial
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level (11, 89). In a cohort study of patients with lung injury and sepsis, achievement of early
adequate fluid resuscitation and late conservative fluid management was associated with the
greatest survival benefit (90). In a randomized trial of patients with pulmonary edema, a lower
fluid balance was associated with fewer ventilator and ICU days (91). With the use of a
conservative fluid strategy and diuresis, the Fluids and Catheter Treatment Trial (FACTT)
increased ventilator-free days with no deleterious effect on organ perfusion in hemodynamically
stable ARDS patients (92).
Observational data from both the ICU and OR suggest that fluid management is
associated with progression to ARDS as well (18, 93-96). Fluid administration improves
perfusion only if it increases stroke volume, and only about 50% of ICU patients are preloadresponsive (97). Once early tissue hypoperfusion is corrected, a conservative fluid strategy and
diuresis should be favored. At a minimum, further fluid administration should be discouraged.
The general consensus for most critically ill ED patients at risk for ARDS, is that early liberal
fluid administration to reverse tissue hypoperfusion should be employed when preloadresponsiveness has been established. An unanswered question includes the true incidence of
preload-responsiveness in critically ill ED patients at risk for ARDS.

Blood product transfusion
The use of blood products is associated with progression to ARDS in at-risk patients. As
an inflammatory syndrome characterized by alveolar epithelial and vascular endothelial injury,
ARDS is notable for early neutrophil sequestration in the lung (98). Transfusion of blood product
is associated with transmission of leukocyte antibodies and biologically active mediators (e.g.
lipids and cytokines), thought to play a role in the pathogenesis of transfusion transfusionassociated acute lung injury (TRALI). The diagnosis of classic TRALI requires a clear temporal
relationship to transfusion, with signs and symptoms occurring within 6 hours. Observational
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data suggests a classic TRALI incidence of close to 10% in critically ill patients (99, 100).
However, in critically ill patients, multiple studies have shown the transfusion of any amount of
blood product to be associated with the progression to ARDS in at risk patients (15, 17-19, 49,
101-105). Expanding the definition of TRALI beyond six hours (i.e. delayed TRALI syndrome),
shows that lung injury may occur in up to 25% of critically ill patients within 72 hours of
receiving a blood transfusion (106). Recipient and transfusion risk factors, such as female
donors, suggest that this incidence is modifiable, and potential targets exist for reducing TRALI
(107).
There has been a general decrease in transfusion in the ICU, but transfusion patterns and
influence of ED transfusion on ARDS has remained largely unexplored. Extrapolation of data
from ICU patients without ARDS at the time of admission, suggests early transfusion plays a
role in ARDS development (15, 17-19, 49). However, in many of these observational studies,
ARDS progression was also associated with other factors (e.g. higher tidal volumes, fluid
balance, etc.), highlighting the complex pathophysiologic interactions in ARDS development
(14). Similar to fluid administration, transfusion may also depend on timing of administration.
Early administration of PRBCs as part of a quantitative resuscitation strategy for severe sepsis
was associated with a decrease in mechanical ventilation, or a trend in that direction, in the
majority of published data (11, 108). However, these trials were not designed to isolate the effect
of transfusion. PRBC administration in this clinical scenario is aimed at improving low central
venous oxygen saturation (ScvO2). Observational data suggests that transfusion does not improve
ScvO2 or organ function (109). In our opinion, given the fact that the weight of evidence does not
show a benefit with PRBC transfusion, the decision to transfuse should be individualized at the
patient level, as opposed to a priori hematocrit triggers. Transfusion should be reserved only for
anemic patients with persistent evidence of tissue hypoperfusion, after a careful assessment of
risk:benefit. Ongoing multicenter trials [e.g. Protocolized Care for Early Septic Shock
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(ProCESS) NCT00510835] will hopefully better define the risk:benefit of potential harm
associated with early transfusion versus persistent global tissue hypoxia (which transfusion may
improve).

Pharmacotherapy
No pharmacological agent designed to alter the primary pathophysiology of ARDS (i.e.
beyond supportive care) has improved clinical outcome. Several agents have been tested for
prevention of ARDS progression. In a propensity-matched observational study, systemic
corticosteroids did not reduce the incidence of ARDS (110). A single center study showed that
prehospital antiplatelet therapy was associated with a reduced incidence of ARDS (111). Using
propensity score matching, a multi-center study failed to show statistical significance with
prehospital aspirin therapy, however the multivariable effect size remained fairly consistent and
statistical significance was almost achieved (p = 0.07) (112). Similarly, propensity score
matching analysis failed to show a decrease in ARDS with statin therapy, in contrast to prior
published data (113, 114). Therapy with azithromycin was shown to decrease mortality and a
13.1% absolute risk reduction in incidence of ARDS (p = 0.064) in patients with Pneumococcal
pneumonia (115). In patients with lung injury, the receipt of a macrolide has been shown to
decrease mortality and mechanical ventilation days, in contrast to patients receiving a
fluoroquinolone or cephalosporin (116). Given the pleiotropic effects of macrolides, prospective
trials addressing the impact of these agents on ARDS prevention and treatment are warranted
(117). Multiple clinical trials targeting various pathways, such as alveolar coagulation,
inflammation,

and

alveolar

fluid

balance

are

currently

in

progress

(http://clinicaltrials.gov/ct2/results?term=ARDS+and+prevention&pg=1).
High minute ventilation and respiratory drive is common in early lung injury, as alveolar
edema and respiratory system compliance worsen. With the induction of paralysis and control of
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the respiratory pattern, neuromuscular blockers (NMB) can mitigate lung injury (theoretically)
by removing dysynchrony and the associated over-distention and end-expiratory collapse
associated with vigorous spontaneous respirations. Furthermore, a decrease in oxygen demand
and subsequent cardiac output through an injured lung, should reduce venous admixture and
pulmonary edema (118). A small RCT also showed that a short duration of NMB reduced
pulmonary and systemic inflammation (119). A multicenter database study of mechanically
ventilated severe sepsis patients found that the receipt of neuromuscular blockers was associated
with a reduction in in-hospital mortality (120). In a multicenter RCT of patients with early
(within 48 hours), severe (PaO2:FiO2 <150) ARDS, a 48 hour infusion of cisatricurium was
associated with decreased hospital mortality censored at 90 days (121). However, this benefit
was restricted to the subgroup of patients with a PaO2:FiO2 <120. These findings make
recommending early NMB for patients at risk for ARDS difficult, and perhaps restricted only to
a very small cohort, such as LIPS ≥ 8 (≈35% chance of developing ARDS) with high ventilatory
demands (34, 118).

Early treatment of infection
A delay in appropriate antimicrobial therapy increases the risk of death in patients with
bacterial septic shock and increases progression rate to ARDS (17, 122). Globally, influenza is
one of the most important causes of respiratory failure and ARDS, especially during seasonal
outbreaks and pandemics (123). The majority of hospitalized patients with seasonal influenza
present from the ED (124). Trials conducted primarily in healthy individuals in the outpatient
setting have demonstrated that neuraminidase inhibitors can reduce illness duration for influenza
patients treated within 48 hours of illness onset (125). Data is limited with respect to patients
with more severe influenza. In patients hospitalized with influenza, oseltamivir has been shown
to reduce mortality and decrease lengths of stay (126-130). A minority of patients receive this
14

therapy however (124). In patients with pandemic influenza A (H1N1), the most common cause
of death is pneumonia and ARDS (131). Observational data suggest that treatment with
neuraminidase inhibitors reduces pneumonia, illness severity, and mortality (132-134). While
antiviral therapy for prevention of ARDS has not been specifically studied, early treatment with
antivirals has also been associated with a decrease in mechanical ventilation days in critically ill
patients (135). It is recommended that early neuraminidase therapy be initiated as early as
possible to reduce complications from influenza for any patient with confirmed or suspected
influenza who is hospitalized, is critically ill, or is at higher risk for complications (125).

Extracorporeal support
The use of extracorporeal membrane oxygenation (ECMO) and pumpless extracorporeal
lung assist (pECLA) in respiratory failure is increasing in frequency. By allowing further
limitation of tidal volume, end-inspiratory stretch, and regional overdistention, these strategies
provide significant lung rest, potential for total strain prevention, and limitation of lung injury
propagation. The current evidence to support ECMO in ARDS can be summarized as follows:
Registry data points to a greater ECMO benefit when instituted early; prospective observational
trials during the H1N1 influenza outbreak suggest that early ECMO referral to high volume
centers is feasible and associated with high survival rates; a multicenter RCT showed that
referral to an ECMO-capable center was associated with a 16% absolute risk reduction for death
or severe disability at six months (136-141). Whether the benefit lies in the ECMO itself or the
referral to highly specialized centers is unclear.
The application of extracorporeal technology to prevent lung injury may seem unlikely
when considering that benefit in ARDS seems to be restricted to the sickest cohort of patients.
However, support for prevention could be extrapolated from the benefit when applied in early
ARDS, as well as technological advances which have increased ease of use and safety profile.
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New pumpless devices can effectively support gas exchange and facilitate very low tidal volume
ventilation (142-144). This has allowed full support without the aid of an endotracheal tube in
case reports (145, 146).
Looking forward, with evidence suggesting that normal lungs can be damaged by even
low stretch ventilation, the early application of pECLA, in experienced, high-volume centers,
could allow lung rest without the aid of a mechanical ventilator in a select cohort of patients at
risk for ARDS (147). This expansion of extracorporeal support beyond life-threatening
hypoxemia to life-threatening ventilator-associated lung injury remains to be tested (148).

Extending ICU-level supportive care to the ED and prehospital environment
Until better genotyping and phenotyping of the individual patients comprising critical
care syndromes (e.g. sepsis and ARDS) occurs, it seems unlikely that narrow mechanistic
intervention trials will work (149, 150). Attempts at de-individualizing care, at the clinician
level, have improved survival in sepsis (151). Similarly, the Checklist for Lung Injury Prevention
(CLIP) attempts to standardize care for patients at risk for ARDS by incorporating evidencebased practices shown to benefit critically ill patients in general (152). While elucidating the
contribution of individual elements (e.g. head of bed elevation and oral care with chlorhexidine)
will likely be topics of academic debate, the efficacy to side effect profile, as well as common
sense, dictate that standard ICU-level of care should be extended to the ED and prehospital
environment when feasible.

Conclusion
The prevalence and clinical trajectory of ARDS is modifiable. The physiology of lung
injury, as well as previous trial failures, dictate that research and intervention should be extended
to earlier times of patient presentation. While the ED has proven to be a highly relevant location
16

for the treatment of time-sensitive emergencies (e.g. stroke, sepsis), this has yet to extend to
mechanical ventilation and ARDS. Several knowledge gaps exist with respect to the long term
effects of ED interventions on ARDS progression and should be investigated further. The
optimal intervention for ARDS prevention while likely be some combination of ventilatory and
non-ventilatory strategies, along with a multidisciplinary collaboration between emergency
physicians, intensivists, nurses, and respiratory therapists.
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Figure Legends
Figure 1. Observational data suggests that acute respiratory distress syndrome (ARDS) onset
ranges from 5 hours to 3.7 days, with a median onset of 2 days. Increasing acuity and prolonged
emergency department (ED) lengths of stay (LOS) for the critically ill suggests that the time
spent in the ED may represent a window of opportunity (“golden hours”) to initiate ARDS
prevention strategies.
Solid circles indicate patients not progressing to ARDS and dashed circles indicate the
development of ARDS.
PaO2:FiO2- partial pressure of arterial oxygen:fraction of inspired oxygen; CRS- respiratory system
compliance; ED- emergency department; LOS- length of stay
Figure 2. Observational data, including patients dying with acute respiratory distress syndrome
(ARDS) and receiving post-mortem examinations, reveal that clinical recognition and diagnosis
of ARDS is missed in a significant percentage of patients. [30-32]
Figure 3. Simplified schematic of the pathogenesis of acute respiratory distress syndrome
(ARDS) with respect to time. After an inciting event, capillary endothelial and alveolar epithelial
injury can occurs in minutes to hours. Activated immune cells (e.g. monocytes and macrophages)
contribute to a cytokine-mediated inflammatory response. This serves to recruit neutrophils,
which play a critical role in ARDS initiation and propagation, through the injured endothelium.
Protein-rich pulmonary edema and subsequent surfactant loss lead to alveolar collapse, hypoxia,
and reduced lung compliance [133,134]. If the primary injury is robust enough, or if modifiable
secondary injuries occur (e.g. high tidal volume, transfusion, delayed sepsis treatment), ARDS
develops, with a typical median onset of two days. Many of these pathogenic mechanisms for
ARDS initiation occur prior to clinical evidence of the syndrome, and this window of pre-clinical
injury forms the basis for ARDS preventive measures.
TNF: tumor necrosis factor; IL: interleukin; ARDS: acute respiratory distress syndrome
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